Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05594095CT.gov SNF Platform Study of HR+/ HER2-advanced Breast Cancer | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT02624700CT.gov 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT01724606CT.gov Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) | — | Completed | — | — | — |
NCT01640665CT.gov Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors | — | Completed | — | — | — |
NCT01234337CT.gov Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT01320111CT.gov Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment | — | Completed | — | — | — |
NCT01194869CT.gov Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer | — | Terminated | — | — | — |
NCT00825734CT.gov Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00828074CT.gov Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer | — | Completed | — | — | — |
Show 17 more trialsShow fewer
NCT00634634CT.gov Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer | — | Completed | — | — | — |
NCT00722072CT.gov Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy | — | Terminated | — | — | — |
NCT00703638CT.gov Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00622466CT.gov Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00573755CT.gov Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00548899CT.gov Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer | — | Completed | — | — | — |
NCT00525161CT.gov Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer | — | Terminated | — | — | — |
NCT00632541CT.gov A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00764972CT.gov Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00954135CT.gov Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients | — | Unknown | — | — | — |
NCT00607438CT.gov A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00493636CT.gov 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy | — | Completed | — | — | — |
NCT00499525CT.gov Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT00544167CT.gov Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer | — | Completed | — | — | — |
NCT00217399CT.gov Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00096434CT.gov Sorafenib in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00101400CT.gov BAY43-9006 - Phase II in Advanced Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | Fudan University | P3 | B · 59 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sorafenib in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →